What Is DSIP? The Delta Sleep-Inducing Peptide, Explained
What exactly is DSIP?
DSIP, delta sleep-inducing peptide, is the common name for a small peptide whose generic drug name is emideltide. It belongs to the broad category of neuropeptides, short chains of amino acids that act on the nervous system, and it is unrelated to melatonin, benzodiazepines, or the "Z-drug" hypnotics like zolpidem despite sharing the general goal of sleep modulation. There is no FDA-approved drug product containing DSIP, and no compounded version of it is currently permitted under 503A pharmacy compounding rules (see FDA 503A bulk substances framework). If you see it sold as a "research chemical," that label reflects its actual regulatory status, not a technicality.
Where did DSIP come from?
DSIP entered the scientific literature in the 1970s, isolated from rabbit brain tissue during research into the electrical correlates of deep, slow-wave ("delta") sleep. The working idea was that a circulating peptide might trigger or promote the deepest stage of non-REM sleep, and early animal work fed decades of follow-up studies looking at DSIP's effects on sleep architecture, stress hormones, and cellular aging. That origin story explains the name, but a peptide discovered through 1970s rabbit brain physiology does not automatically translate into a proven human therapeutic, and the intervening decades of research have not closed that gap.
Does DSIP actually improve human sleep?
The honest answer is: weakly, and only in old, small data. The main human evidence is a double-blind study of DSIP in chronic insomnia patients from 1992, which is the kind of small trial that can generate a signal worth studying further but cannot establish efficacy or safety on its own (Effects of delta sleep-inducing peptide on sleep of chronic insomniac patients, 1992). There is no modern, adequately powered, replicated randomized trial establishing that DSIP improves sleep onset, sleep maintenance, or sleep quality in humans. Separately, DSIP has been studied as an adjunct during general anesthesia, where it measurably altered EEG and bispectral index readings and heart rate variability, a pharmacodynamic finding, not evidence of standalone sleep benefit for someone trying to sleep at home (DSIP and isoflurane anesthesia, 2009).
What about the other claimed effects, cortisol, aging, pain?
Most of the DSIP literature after the 1990s is not about sleep at all. It is largely Russian- and Ukrainian-language animal and in vitro work on oxidative stress markers, mitochondrial enzyme activity, lysosomal proteolysis, and hepatic function during physiological aging in rats (antioxidant enzyme gene expression in aging rats, mitochondrial electron transport chain effects, aging rats, lysosomal membrane and proteolysis effects, aging rats, hepatocyte function in foot-shock stress, rats). There is also older human data showing DSIP infusion reduced circulating ACTH after intravenous injection, a hormonal effect, not a clinical outcome (ACTH reduction after IV DSIP, 1989). None of this animal and hormonal work supports marketing claims about DSIP as an anti-aging, cortisol-lowering, or pain-relief agent in humans. It supports further research questions, and that is a different thing.
For context on how cortisol and sleep actually interact clinically in a condition where the evidence is much stronger, glucocorticoid replacement in adrenal insufficiency has documented, permissive effects on REM sleep and sleep consolidation, illustrating the kind of endocrine-sleep evidence base DSIP does not currently have (glucocorticoid replacement and REM sleep in adrenal insufficiency, 2000).
Claimed use versus evidence tier: a quick reference
| Claimed use | What the evidence actually shows | Evidence tier |
|---|---|---|
| Improves sleep onset/quality in insomnia | One small double-blind human trial from 1992, not replicated since | Single small trial, dated |
| Reduces cortisol/ACTH | IV DSIP lowered plasma ACTH in a small human study | Small pharmacodynamic study |
| Anti-aging / antioxidant effect | Multiple rodent studies on oxidative stress and mitochondrial markers | Animal/in vitro only |
| Pain relief | No human clinical trial data provided in the sourced literature | Not established |
| Safe for repeated home use | No modern safety trial; used historically as an anesthesia adjunct under monitored conditions | Not established for self-administration |
| Legally compoundable | Nomination withdrawn; not on the 503A list; committee voted against adding it | Not permitted |
Use this table as a filter before trusting any DSIP marketing claim: ask which row the claim actually belongs to, then ask whether that tier is strong enough to justify the claim being made.
Is DSIP legal to buy or have compounded in 2026?
DSIP has no FDA-approved indication. Its nomination for the FDA's Category 2 list, the list flagging bulk substances that may present significant safety risks in compounding, was withdrawn by the nominators, not approved (current as of 04/22/2026, FDA Category 2 bulk substances page). Withdrawal of a safety-risk nomination is not the same as regulatory clearance, and DSIP does not appear on the FDA's 503A bulk drug substances list, meaning pharmacies have no enforcement-discretion basis to compound it as a human drug (503A bulk substances framework). On July 23-24, 2026, the FDA's Pharmacy Compounding Advisory Committee considered emideltide (DSIP) for that 503A list and voted against recommending it, which closes rather than opens a near-term legal compounding pathway (meeting record). For the current status of DSIP and related peptides in one place, see the FDA Peptide Status Tracker.
What is established, what is plausible, and what is not established
Established: DSIP is a real, structurally defined peptide first studied in the 1970s, with documented pharmacodynamic effects on EEG and hormone levels in small human studies, and it has no FDA-approved use.
Plausible but unproven: DSIP may influence some aspect of sleep architecture in humans, based on one small 1992 trial, and it may have antioxidant or metabolic effects worth further study, based on rodent data.
Not established: that DSIP reliably improves sleep quality or duration in general users, that it is safe for repeated unsupervised use, that it treats pain, or that it has any legitimate current compounding or purchasing pathway in the United States.
Where this fits if you are comparing sleep options
If insomnia is the actual problem being solved, it is worth separating what DSIP claims to do from options with a stronger evidence and regulatory footing. See DSIP for sleep: what the evidence actually shows for a deeper look at the 1992 trial and its limits, DSIP versus melatonin for a head-to-head on evidence quality, and DSIP versus prescription sleep aids if a discontinuation or comparison question brought you here. Readers weighing prescription alternatives may also want the zolpidem discontinuation protocol or trazodone discontinuation protocol pages. For the underlying mechanism question, see how DSIP is thought to work, and for the fuller regulatory picture, DSIP's FDA status in 2026.
If sleep problems are severe, persistent, or accompanied by chest pain, breathing pauses witnessed by another person, confusion, or thoughts of self-harm, that calls for prompt evaluation by a clinician or urgent care, not a peptide sourced outside the pharmaceutical supply chain.